Sequentify, a Weizmann Institute spinoff that develops synthetic biology and AI software to enable rapid targeted DNA sequencing, announced Stanford Institute for Stem Cell Biology and Regenerative Medicine will be using its NGS targeted panels for acute myeloid leukemia (AML) somatic mutation detection. Applications include basic and translational research into AML pathogenesis and novel therapeutic target identification, according to the company.
Founded in 2021, Sequentify democratizes genomics by providing DNA library preparation for Next Generation Sequencing (NGS) and AI software that enables fast, cost-effective and automated sequencing. Sequentify’s NGS products are based on its InfiniSeq proprietary platform and include cancer diagnostics, carrier screening, virology, and other applications.
“We are excited to work with Stanford Medicine, a world leading research institute and hospital, on implementing cost effective and high throughput NGS sequencing for myeloid conditions,” says Tom Fleischer, co-founder and CEO of Sequentify.
Further reading: CAP Molecular Proficiency Testing Programs Show Accurate Clinical Cancer Sequencing Results
Sequentify’s Infiniseq technology condenses sample preparation lab time to only 3.5 hours from DNA to sequencing with one tube reaction, full automation support, and dramatic cost reduction, the company says. The patent-pending InfiniSeq technology is adjustable to most sequencing machines and fits into any lab workflow.
